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AbstrAct
Introduction Smoking is a major cause of ill health and 
is associated with several diseases including cancer, 
coronary heart disease and stroke. Many psychological and 
pharmacological smoking cessation treatments are available 
and although they are undoubtedly the most cost-effective 
health interventions available, many people still fail to maintain 
cessation in the longer term. Recently, National Institute for 
Health and Care Excellence called for comparative studies to 
determine the short-term and long-term effectiveness of Allen 
Carr’s Easyway (ACE) method of stopping smoking. This study 
will compare the efficacy of the ACE programme and a 1–1 
counselling service available via the National Health Service.
Methods and analysis A two-arm, parallel-group, blinded, 
randomised controlled trial will be conducted with people 
who smoke tobacco cigarettes, are aged ≥18 years and are 
motivated to quit. Exclusion criteria comprise self-reported 
mental health condition, pregnancy or respiratory disease such 
as chronic obstructive pulmonary disease or emphysema. The 
primary treatment outcome is smoking cessation 26 weeks 
after treatment. Participants will be analysed on an intention 
to treat basis at the point of randomisation. Before being 
randomised, the research team will not inform participants 
which two treatments are being compared. Once randomised 
researchers will be blinded to participant condition, and 
participants will be blinded to the condition they are not 
assigned to. Logistic regression will be used to estimate the 
effectiveness of the treatment condition on smoking cessation 
at 26 weeks. The following covariates will be included: 
baseline quit efficacy (at inclusion), age (at inclusion), gender 
and baseline nicotine dependency.
Ethics and dissemination Approval was granted by London–
Fulham Research Ethics Committee (ref: 16/LO/1657). The 
study’s findings will be published in peer-reviewed journals 
and disseminated at national and international conferences.
trial registration number  ClinicalTrials. gov identifier 
number: NCT02855255. ISRCTN registration number: 
ISRCTN23584477; Pre-results.
IntroductIon
Dependence on nicotine has long been a 
problem and although statistics from the 
WHO1 show that the prevalence of tobacco 
smoking is declining worldwide, there 
are still a significant number of people, 
1.1 billion in 2015, who continue to smoke.1 
Smoking is a major cause of ill health and 
is associated with several diseases including 
cancer, coronary heart disease and stroke. In 
the UK alone in 2014, there were 9.6 million 
smokers, with 78 000 deaths attributed to 
smoking.2 
Many smokers want to quit and often make 
several attempts to do so, but the majority 
fail due to both physiological and psycho-
logical factors.3 Over the years, researchers 
have sought to develop effective cessation 
treatments in an effort to provide education 
and support. Consequently, many psycho-
logical and pharmacological treatments are 
available to help smokers quit, and although 
these types of intervention are undoubtedly 
the most cost-effective interventions avail-
able,4 many people fail to maintain smoking 
cessation in the longer term.5 In 2014, it 
was reported that 37% of smokers made an 
attempt to quit but only 19% were actually 
successful.6
It is important to understand the relative 
efficacies of various interventions designed 
to help people quit, and recently NICE 
called for comparative studies to deter-
mine the short-term and long-term effec-
tiveness of Allen Carr’s Easyway (ACE) 
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Protocol
strengths and limitations of this study
 ► This study adopted a blinded randomised controlled 
trial design.
 ► Chemical verification of quit success.
 ► Comparison of two common smoking cessation 
interventions.
 ► No ‘no treatment’ control.
 ► Although researchers are blinded, therapists 
delivering the interventions are not blinded, that 
is, each intervention is delivered by experienced 
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method of stopping smoking. While the ACE method 
is well established and its efficacy has received some 
empirical support (see Dijkstra et al7), there has not to 
date been a randomised control trial (RCT) testing the 
efficacy of this method. Consequently,  ACE method 
and a 1–1 counselling service available via the NHS 
will be compared. By comparing the ACE  method to 
a NHS delivered treatment programme, an estimate of 
the relative effectiveness of ACE in comparison to the 
NHS service can be made. This will potentially inform 
future judgements about the use of this method by 
private and public healthcare providers. The findings 
will add to the evidence base around the use of the NHS 
stop smoking service and the ACE method.
MEthods
design
A two-arm, parallel-group, blindedi, RCT.
treatment setting/site
All intervention sessions for the NHS and ACE 
programmes will be delivered on the London South Bank 
University (LSBU) Southwark campus and the ACE site 
in London, SW20. They begin in February 2017 and will 
run for 8 months.
study population
People who smoke tobacco cigarettes and are motivated 
to quit.
Inclusion and exclusion criteria
Participants will be eligible provided they are at least 
18 years of age, are current smokers who intend to quit 
and are prepared to be assigned randomly to one of two 
treatment conditions. Individuals who, on being asked 
at the point of recruitment, would prefer an NHS-pro-
vided treatment, are currently in another RCT or similar 
research project, disclose that they have a mental health 
condition, are pregnant or have a respiratory disease 
such as chronic obstructive pulmonary disease or emphy-
sema will be excluded. Additionally, individuals who feel 
they are unable to reach the treatment location (LSBU’s 
Southwark Campus or London SW20) for treatment and 
follow-up will also be excluded.
Interventions
ACE programme
The ACE intervention involves a single group session 
with up to 25 attendees, led by a trained facilitator. 
The 5–6 hour session broadly comprises elements of 
cognitive behavioural therapy (CBT) and ends with a 
short hypnotherapy/relaxation exercise. Participants 
are encouraged to carry on smoking as normal right up 
until they attend the clinic, and during the session they 
are encouraged to smoke as normal during scheduled 
i With researchers blind to participant condition, and participants blind 
to the condition they are not assigned to
smoking breaks (around every 45–60 min). Participants 
are assisted in identifying positive expectancies they 
associate with smoking (eg, pleasure, support, crutch or 
other benefits) before working towards the conclusion 
that the belief that smoking provides these benefits is, in 
fact, erroneous and harmful. Participants also achieve a 
basic understanding of how the psychological and phar-
macological mechanisms of nicotine addiction facilitate 
the maintenance of erroneous and problematic beliefs. 
These sessions end with a ‘ritual’ final cigarette followed 
by an approximately 20 min period of hypnotherapy—a 
light relaxation exercise that reinforces the main points 
of the session. At the end of each session, each partic-
ipant is asked to make a written record of what it was 
about their life as a smoker that made them want to 
stop. Following each session, the clinical team will call, 
email or SMS text to the participant on day 1, and again 
at 3, 7, 10, 14, 21, 30, 45, 60, 75, and 90 days with a short 
courtesy message such as ‘hope you’re well. Please don’t 
hesitate to get in touch if you have any questions at all’, 
‘hope all is well with you. Don’t forget we’re here if you 
have any questions’.
NHS smoking cessation programme
The NHS intervention comprises the NHS stop smoking 
service currently offered at Guy’s and St Thomas’ NHS 
Foundation Trust and Lambeth Public Health. This 
constitutes a single session of around 30 min which 
combines motivational interviewing and CBT, followed 
by four follow-up sessions. The initial session involves 
informing the client about the treatment programme, 
assessing current smoking, readiness to quit and past 
quit attempts. Participants are then advised on the oper-
ation of nicotine dependence, the mechanics of with-
drawal and given advice on changing routine. The use, 
pros and cons of various nicotine replacement thera-
pies (NRTs) are also outlined. A quit date is set (within 
2 weeks of receiving the intervention) and the impor-
tance of complete abstinence discussed. Finally, a carbon 
monoxide test is administered and explained. Before the 
session finishes, participants are assisted in identifying 
high-risk situations in the coming week and develop 
quit action plans. This treatment is combined with 
the prescribed NRT of the patients’ choice (including 
Varenicline). One, 2 and 3 weeks post quit date, shorter 
meetings (approximately 10 min) are arranged, respec-
tively. These involve a progress check, a discussion 
around withdrawal symptoms and coping, a check on 
NRT supplies, a reflection on difficult situations encoun-
tered, a carbon monoxide test and planning for high-
risk situations in the coming week. The importance of 
abstinence is finally reinforced. Four weeks after the quit 
date, an approximately 10 min meeting checks on prog-
ress, measures carbon monoxide, advises on continued 
use of medication, discusses craving and urges and diffi-








pen: first published as 10.1136/bmjopen-2017-016867 on 14 December 2017. Downloaded from 
 3Wood KV, et al. BMJ Open 2017;7:e016867. doi:10.1136/bmjopen-2017-016867
Open Access
Top-ups and resets
Both treatments contain, as standard, options to reset/top 
up quit dates. The ACE provision includes the option for 
clients to ‘top-up’ their treatment in two further sessions. 
These second and third sessions broadly follow the same 
format (approximately 3.5 hours) but contain more inter-
action and a smaller group (up to 15 clients) and can be 
carried out face-to-face or online. They can take place 
up to 3 months from the initial session. The clinician will 
provide contact details through which these sessions can 
be arranged. Should these optional sessions be taken up 
by a participant then the use of a top-up and the date will 
be recorded by the clinician on the participant schedule 
and the subsequent testing dates will be based on the 
reset date. The primary outcome will be counted from 
the reset date (eg, prior cigarettes consumed up to that 
point will be disregarded). The NHS arm contains the 
option for participants to be given a chance to reset their 
quit date, at the discretion and suggestion of the clini-
cian. Should a reset be offered, the use of a reset and 
the revised date will be recorded, and the subsequent 
testing dates will be based on the reset date. The primary 
outcome will be counted from the reset date (ie, prior 
cigarettes consumed up to that point will be disregarded).
Both NHS and ACE treatments offer top-ups that are 
part of treatment as usual, so it is reasonable that the 
smoke-free period starts from the date of the top-up (the 
top-up is part of the normal ‘dosage’ of the method). 
Therefore, all participants will have to be smoke-free for 
6 months (primary outcome), in line with Russell 6 Stan-
dard, from the point they receive the treatment. People 
who do not slip more than the defined number of times, 
do not attend top-ups and still maintain from the end 
of treatment to the final outcome point can of course 
self-recover. Where participants engage in a subsequent 
data collection point (ie, 4 weeks) before top-up, these 
data will be held, but a new set of data will be collected 
and used in subsequent analysis (see figure 1 for diagram 
displaying flow of participants through the study).
An alternative approach would be to track all partici-
pants from the end of a prespecified ‘grace period’ which 
would allow for spontaneous resets. However, such a 
response would effectively mean that the actual smoke-
free period between end of treatment and the primary 
outcome measure point could vary considerably. If there 
are differences in the number of resets/top-ups used 
between treatment arms, this would introduce non-trivial 
systematic bias into the final analysis. In order to explore 
how the use of top-ups/resets affects outcomes, we will 
undertake secondary analysis looking only at those who 
did not use resets/top-ups (and, if appropriate in terms 
of statistical power, comparing rates between those that 
do and do not between arms).
outcomes
Primary outcome measures
The primary outcome for the trial is the proportion of 
participants who maintain sustained abstinence for 26 
weeks after their quit date. Abstinence is defined using 
the Russell 6 Standard (ie, fewer than five incidents of 
smoking from the quit date, including all participants 
lost to follow-up as failed treatment, and confirming all 
successful quits via breath carbon monoxide testing). The 
intention to treat principle will be followed, and those 
lost to follow-up will be considered as a failed quit.8
Secondary outcome measures
The following secondary outcome measures are being 
assessed in all participants at 4, 12 and 26 weeks post quit 
date: self-reported maintenance of smoking cessation: measured 
by current cessation, number of cigarettes in past week/
month/since last session; use of nicotine replacement therapy/
nicotine containing products: participants will be asked to 
answer yes/no to the following: ‘since we last met, have 
you regularly used any of the following?’ and ‘are you 
planning on using any of the following in the future?’ 
e-cigarettes, nicotine patches, nicotine gum, champix 
and other; perceived value of being nicotine free: measured 
on a scale of 1–7 (strongly disagree–strongly agree) to the 
following items: ‘being nicotine free is of value to me’, 
‘I value being nicotine free’, ‘having no nicotine in my 
system is/would be beneficial to me’; satisfaction with life9: 
a well-validated 5-item scale designed to measure global 
cognitive judgements of one’s life satisfaction. Partici-
pants indicate how much they agree or disagree with each 
of the five items using a scale of 1–7 (strongly disagree–
strongly agree); quit efficacy: measured on a scale of 1–7 
(strongly disagree–strongly agree) to the following items: 
‘I can achieve my aims to quit smoking’, ‘I can cope with 
the demands of quitting smoking’, ‘it is unlikely that I will 
do well at quitting smoking’, ‘I think I can perform well at 
quitting smoking’. Readiness to change smoking behaviour10: 
a well-validated measure of readiness to consider smoking 
cessation. Measured on a scale of 1 (lowest level of read-
iness) to 10 (highest level of readiness). Responses 1–3 
are indicative of no plans to quit smoking, 4–6 range 
from thinking about quitting to planning to quit in the 
next 6 months and 7–10 range from planning to quit in 
the next 30 days to having already quit smoking. Adverse 
events: information regarding any adverse events relating 
to the participant’s health and well-being and whether 
they are related to treatment.
sample size
Tests are powered to detect superiority. Based on data 
from Dijkstra et al,7 an attrition rate between recruitment 
and final follow-up (at 6 months) of 30% is indicated. 
To ensure sufficient participants in the final sample 
at this rate, an initial sample of 620 participants will be 
sought (310 per intervention group). To detect differ-
ences in success rates (at 6 months) in treatments with 
success rates of 30% and 50%, respectively (powered at 
0.95, alpha 0.05, and adjusting to account for a 25% loss 
to follow-up), a sample size of 480 would be required. 
To detect differences between 20% and 40% quit rates 
(with the same assumptions), a sample of 400 would be 
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Figure 1 Process diagram indicating the flow of participants through the study. ACE, Allen Carr’s Easyway; LTF, lost to follow-
up; NHS, National Health Service.
required. To detect differences between 50% and 70%, 
a sample size of 566 is needed. Thus, the study will be 
adequately powered to detect meaningful differences 
in the expected range, with lost to follow-up rates in the 
region of previous research or somewhat above.
recruitment
People will be informed of the trial through local place-
ment of posters, leaflets to residential properties, book-
lets to major employers, employment networks and 
councils, webpages at LSBU, social media campaigns 
and radio advertisements. People interested in enrolling 
will be invited to contact LSBU to provide contact details 
and will be sent (via email or post) an information sheet 
containing written information about the study. Within 
2 days, potential participants will be contacted by phone 
and undergo eligibility prescreening. At this point, they 
will not be informed which two interventions are being 
compared in the study. If eligible, participants will be 
asked about demographics, nicotine dependence and 
prior quit attempts to allow for stratified randomisa-
tion into the trial. Within 2 days of being screened, the 
research team will send eligible participants a consent 
form (via post or email). As this stage is before intention 
to treat or condition allocation, no restrictions on contact 
attempts are placed on this stage. On gaining written 
consent, participant’s details will be sent to the indepen-
dent randomiser for allocation. Once randomised, partic-
ipants will see the research team four times (baseline, 4 
weeks, 12 weeks and 26 weeks). They will be paid £15 cash 
for attending each measurement point and regardless 
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of quit outcome, they will be entered into a prize draw 
to win a Caribbean holiday for two, an iPad or a gym 
membership.
randomisation, allocation concealment and sequence 
generation
Participants will be randomised to condition by Sarah 
White (study statistician) using the Kang et al’11 ‘Covariate 
Adaptive Randomization Program’ (V.1.0) software 
package. Four stratification factors, each at two levels, will 
be used: nicotine dependence (determined by the Fager-
strom Test for Nicotine Dependence (FTND) question-
naire12), number of prior quit attempts, age and gender. 
Participants will be assigned to the ACE and NHS 1–1 
intervention groups in a ratio of 1:1 (310 in each).
blinding
Participants will be blind to both interventions until 
randomised and once allocated will be blind to the 
alternative intervention. Members of the trial steering 
committee, management committee and other team 
members (with the exception of the statistician/rando-
miser) will remain blind to treatment allocation until the 
last follow-up is completed and the data recorded, and 
the clinical team is not authorised to reveal it.
data collection, management and analysis
All data will be collected via paper questionnaires, apart 
from carbon monoxide readings where a Smokerlyzer 
piCO analyser will be used. Participant data will be entered 
by the research team and will only be linked directly with 
their participant ID code. Personal data (eg, identifiable 
data) will be accessible to the research team (as part of 
the screening process), the statistician and the direct care 
team. Hard copies of data will be destroyed via confiden-
tial waste disposal 5 years after the research findings have 
been published. Electronic copies of data will be stored in 
two archives. In both cases, only anonymous data will be 
archived. They will be archived at London South Bank Data 
Archive and a national data repository such as the UK Data 
Archive. For more information about data management 
and monitoring, please see the study research protocol.
statistical analyses
A senior statistician determined the sample size and 
wrote the statistical analysis plan which was subsequently 
agreed by the steering committee. All statistical analyses 
will be performed using SPSS V.24 software. Participants 
will be analysed on an intention to treat basis at the point 
of randomisation. 95% CIs will be presented for all anal-
yses. Missing data will be replaced by the mean within 
condition score. The following stratification variables will 
be included as covariates in all regression models: base-
line quit efficacy (at inclusion), age (at inclusion), gender 
and baseline nicotine dependency. These covariates have 
been selected as they have been shown to influence 
treatment success, and we wish to investigate the unique 
effects of treatment across a demographically heteroge-
neous sample.
Primary outcome analysis
Participants for whom smoking cessation cannot be 
confirmed (ie, are lost to follow-up) will be included 
in the analysis as failed quits, in line with the Russell 6 
Standard. Logistic regression will be used to estimate 
the effectiveness of the treatment condition on smoking 
cessation at 6 months.
A series of sensitivity analyses will be conducted to 
assess the robustness of primary results with regards to 
definition of the primary outcome. To investigate if the 
differential effects of interventions are present at each 
time point (4 and 12 weeks), the primary analysis will be 
repeated twice, the dependent variable being smoking 
cessation confirmed at 4 and 12 weeks. The primary anal-
ysis will be repeated on smoking cessation outcomes at 
both 12 and 26 weeks using only participants who did not 
‘reset’ their quit dates (NHS arm) or attended a top-up 
session (ACE arm). This is preferable to including them 
as failed quits, as many may in fact be successful cessa-
tions, while also attending a top-up.
Secondary smoking outcomes
Use of NRT in each treatment arm will be tested by 
conducting a logistic regression. Treatment arm and treat-
ment success will be included as the independent variables.
Secondary non-smoking outcomes analyses
To analyse the take up of treatment between condi-
tions, a logistic regression will be undertaken on treat-
ment completion (operationalised as attendance at 
the ACE session and attendance at all 5 weeks of the 
NHS sessions). Multilevel regression models with time 
of measurement (4 weeks, 12 weeks and 26 weeks) will 
be undertaken with perceived value of being nicotine 
free, readiness to change, intentions to re-engage, life 
satisfaction as the dependent variables and treatment 
arm as the independent variable. Planned compari-
sons between treatment arms at each time point will be 
undertaken.
Plan of presentation
A CONSORT diagram will be used to describe the 
sampling, drop-outs and randomisation.
Ethics and dissemination
This protocol has been independently peer reviewed by 
Professor Robert West, University College London and 
meets requirements of London - Fulham Research Ethics 
Committee, reference number 16/LO/1657. In addi-
tion, this protocol has been reviewed and approved by the 
Research Ethics Committee at London South Bank Univer-
sity. Informed consent: Informed written consent will be 
obtained by the research team. Participants will be sent 
an information sheet containing information about the 
study and eligible participants will be required to provide 
informed written consent before being randomised. At the 
end of the study, a non-technical summary of the results 
will be prepared for participants. The study findings will be 
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disseminated through national and international confer-
ence presentations and will be reported in peer-reviewed 
journals.
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